HBM FY25 profit jumps to US$ 92 million; revenue more than tripled to US$ 160 million

Reuters03-30
HBM FY25 profit jumps to US$ 92 million; revenue more than tripled to US$ 160 million
  • HBM Holdings posted profit of US$ 92 million for year ended Dec. 31, 2025, versus US$ 2.7 million a year earlier.
  • Revenue surged 314.6% to US$ 160 million, driven by higher molecule license revenue tied to strategic collaborations and new out-licensing.
  • Basic earnings per share rose to US$ 0.12, while cash and cash equivalents climbed to US$ 400 million.
  • R&D costs increased to US$ 40 million as programs advanced, while administrative expenses expanded to US$ 24 million on higher employee and professional costs.
  • Business updates included a global multi-year collaboration with AstraZeneca with up to US$ 4.4 billion in potential milestones, a Bristol Myers Squibb multispecific-antibody deal with up to US$ 1.035 billion in milestones, and an Otsuka license for HBM7020 with up to US$ 623 million in milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260330-12079259), on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment